Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
$2.24M Buy
44,378
+2,961
+7% +$145K 0.46% 57
2015
Q4
$2.09M Sell
41,417
-4,241
-9% -$214K 0.44% 62
2015
Q3
$2.15M Sell
45,658
-295
-0.6% -$15.7K 0.47% 67
2015
Q2
$2.5M Sell
45,953
-2,031
-4% -$114K 0.49% 64
2015
Q1
$2.63M Buy
47,984
+1,070
+2% +$60.6K 0.52% 57
2014
Q4
$2.54M Buy
46,914
+710
+2% +$39.6K 0.53% 55
2014
Q3
$2.61M Sell
46,204
-495
-1% -$27.8K 0.61% 49
2014
Q2
$2.58M Buy
46,699
+1,184
+3% +$64.6K 0.6% 54
2014
Q1
$2.47M Buy
45,515
+382
+0.8% +$19.8K 0.61% 50
2013
Q4
$2.15M Sell
45,133
-11,120
-20% -$508K 0.71% 41
2013
Q3
$2.56M Buy
56,253
+1,196
+2% +$54.6K 0.98% 27
2013
Q2
$2.44M Buy
+55,057
New +$2.46M 1.01% 25

Other funds holding MRK

Smith Hayes Advisers's MRK Position: Q1 2016 in Review

Smith Hayes Advisers increased its Merck (MRK) stake by 7.1% in Q1 2016, buying an estimated $145K and bringing the position to 44,378 shares worth $2.24M. The position accounts for 0.46% of the portfolio, ranked #57.

Smith Hayes Advisers first reported a position in MRK in Q2 2013 and has held it in 12 quarters since. The position peaked at $2.63M in Q1 2015. 1,744 funds tracked by Wall St. Rank hold MRK as of Q1 2016.

  • Smith Hayes Advisers held 44,378 shares of Merck worth $2.24M as of Q1 2016.
  • Smith Hayes Advisers bought 2,961 Merck shares in Q1 2016, an estimated $145K.
  • Merck made up 0.46% of Smith Hayes Advisers's portfolio in Q1 2016, its #57 holding.
  • Smith Hayes Advisers first reported a position in Merck in Q2 2013 and has held it in 12 quarters since.
  • Smith Hayes Advisers's Merck position peaked at $2.63M in Q1 2015.
  • 1,744 funds tracked by Wall St. Rank held Merck as of Q1 2016.

Based on Smith Hayes Advisers's 13F filing for Q1 2016, filed 16 May 2016.